SYNTARA LIMITED - Announcements

Market Cap $28.65M Add to my watchlist

Healthcare

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Announcements

Filter Results

All Price Sensitive Only

SNT	Pharmaxis Announces New Board Appointment		25/07/12	88.67KB	Share
SNT	Appendix 3B - Exercise of Employee Options		24/07/12	91.64KB	Share
SNT	Quarterly Report to Shareholders - June 2012		17/07/12	272.81KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	17/07/12	109.23KB	Share
SNT	Pharmaxis Quarterly Investor Conference Call		16/07/12	21.6KB	Share
SNT	Ceasing to be a substantial holder		10/07/12	28.64KB	Share
SNT	Becoming a substantial holder		05/07/12	228.74KB	Share
SNT	Ceasing to be a substantial holder		04/07/12	46.82KB	Share
SNT	Proposed Issue of Performance Rights to CEO		02/07/12	94.61KB	Share
SNT	Appendix 3B - Grant of Employee Performance Rights		02/07/12	96.56KB	Share
SNT	Appendix 3B - Exercise of Employee Options		02/07/12	91.57KB	Share
SNT +UBS	Becoming a substantial holder from UBS		29/06/12	233.56KB	Share
SNT	Change of Director's Interest Notice		28/06/12	86.95KB	Share
SNT	Appendix 3B		28/06/12	141.02KB	Share
SNT	PHARMAXIS WELCOMES BRONCHITOL PBS LISTING ANNOUNCEMENT		25/06/12	82.26KB	Share
SNT	Ceasing to be a substantial holder		19/06/12	37.73KB	Share
SNT	Becoming a substantial holder		15/06/12	217.01KB	Share
SNT	Additional Data Bronchitol Reduces Risk of Exacerbations	PRICE SENSITIVE	08/06/12	109.51KB	Share
SNT	Appendix 3B - Exercise of Employee Options		01/06/12	97.54KB	Share
SNT	Bronchitol Commercial Progress in Europe	PRICE SENSITIVE	01/06/12	132.55KB	Share
SNT	Appendix 3B - Exercise of employee options		21/05/12	97.6KB	Share
SNT	Pharmaxis Submits US New Drug Application for Bronchitol	PRICE SENSITIVE	21/05/12	83.46KB	Share
SNT	Amended - Ceasing to be a substantial holder		16/05/12	61.89KB	Share
SNT	Ceasing to be a substantial holder		10/05/12	59.33KB	Share
SNT	Appendix 3B Exercise of Employee Options		02/05/12	97.58KB	Share
SNT	Final Director's Interest Notice		01/05/12	11.59KB	Share
SNT	Pharmaxis Appoints New Chairman		01/05/12	77.38KB	Share
SNT	Investor Presentation		27/04/12	3.6MB	Share
SNT	Pharmaxis Receives Approval to Market Bronchitol in the EU	PRICE SENSITIVE	20/04/12	82.13KB	Share
SNT	Pharmaxis Quarterly Report to Shareholders March 2012		18/04/12	214.02KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	18/04/12	109.33KB	Share
SNT	Pharmaxis Quarterly Investor Conference Call		17/04/12	21.55KB	Share
SNT	PXS Completes Phase II study with ASM8 in asthma patients	PRICE SENSITIVE	17/04/12	108.62KB	Share
SNT	Becoming a substantial holder		17/04/12	188.55KB	Share
SNT	Ceasing to be a substantial holder		13/04/12	26.48KB	Share
SNT	Becoming a substantial holder		11/04/12	227.14KB	Share
SNT	Pharmaxis Announces Agreement for EU Supply of Bronchitol	PRICE SENSITIVE	29/03/12	80.08KB	Share
SNT	European Regulatiry Update on Bronchitol	PRICE SENSITIVE	16/03/12	78.65KB	Share
SNT	Bronchitol to be Reimbursed in Australia	PRICE SENSITIVE	14/03/12	83.48KB	Share
SNT	Change of Director's Interest Notice		27/02/12	72.18KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	03/02/12	267.62KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/12	109.24KB	Share
SNT	Quarterly Report to Shareholders		24/01/12	402.91KB	Share
SNT	Quarterly Investor Conference Call		23/01/12	21.6KB	Share
SNT	Change of Director's Interest Notice		30/12/11	70.18KB	Share
SNT	Becoming a substantial holder		22/12/11	36.48KB	Share
SNT	Pharmaxis Files PBAC Minor Resubmission for Bronchitol	PRICE SENSITIVE	20/12/11	78.36KB	Share
SNT	Change of Director's Interest Notice - D Hanley		16/12/11	73.05KB	Share
SNT	Change of Director's Interest Notice - J Villiger		16/12/11	72.83KB	Share
SNT	Change of Director's Interest Notice - Delaat		16/12/11	72.53KB	Share
SNT	Appendix 3B - Exercise of Employee Options		16/12/11	97.6KB	Share
SNT	Appendix 3B - Rights Offering Second Settlement		16/12/11	100.29KB	Share
SNT	Phase 3 Trial in Bronchiectasis Reaches Recruitment Target	PRICE SENSITIVE	13/12/11	106.04KB	Share
SNT	Results of Retail Entitlement Offer		13/12/11	80.92KB	Share
SNT	Appendix 3B		29/11/11	100.87KB	Share
SNT	Change of Director's Interest Notice		25/11/11	71.51KB	Share
SNT	Entitlement Offer - Letter to Ineligible Shareholders		24/11/11	45.29KB	Share
SNT	Retail Offer Booklet	PRICE SENSITIVE	24/11/11	2.1MB	Share
SNT	Results of Meeting		22/11/11	82.89KB	Share
SNT	CEO Presentation to 2011 AGM		21/11/11	2.72MB	Share
SNT	Chairman's Address 2011 AGM		21/11/11	84.97KB	Share
SNT	Institutional Component of Entitlement Offer	PRICE SENSITIVE	18/11/11	96.82KB	Share
SNT	ASX Circular - Entitlement Offer		16/11/11	52.54KB	Share
SNT	Appendix 3B		16/11/11	101.51KB	Share
SNT	Notice under section 708AA(2)(f)		16/11/11	40.98KB	Share
SNT	Capital Raising Presentation		16/11/11	1.46MB	Share
SNT	ProRata Entitlement Offer to Raise up to Approximately $80m		16/11/11	40.62KB	Share
SNT	Trading Halt	PRICE SENSITIVE	16/11/11	67.05KB	Share
SNT	Pharmaxis Announces PBAC Decision on Bronchitol	PRICE SENSITIVE	09/11/11	80.69KB	Share
SNT	Investor Presentation		25/10/11	1.73MB	Share
SNT	Reinstatement to Official Quotation	PRICE SENSITIVE	24/10/11	28.28KB	Share
SNT	Pharmaxis Announces Positive Bronchitol Opinion for Europe	PRICE SENSITIVE	24/10/11	104KB	Share
SNT	Investor Conference Call - Bronchitol EU Re-examination		21/10/11	22.08KB	Share
SNT	Suspension from Official Quotation	PRICE SENSITIVE	20/10/11	151KB	Share
SNT	Trading Halt	PRICE SENSITIVE	17/10/11	67.36KB	Share
SNT	Notice of 2011 Annual General Meeting/Proxy Form		17/10/11	618.9KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	12/10/11	109.05KB	Share
SNT	Quarterly Report to Shareholders - September 2011		12/10/11	292.96KB	Share
SNT	Quarterly Investor Conference Call		11/10/11	21.56KB	Share
SNT	Change in substantial holding		10/10/11	53.71KB	Share
SNT	2011 Annual Report to Shareholders		29/09/11	1.15MB	Share
SNT	Phase II Trial in Allergic Asthma Completes Recruitment	PRICE SENSITIVE	29/09/11	90.81KB	Share
SNT	Update on EU Bronchitol Marketing Application	PRICE SENSITIVE	28/09/11	91.48KB	Share
SNT	Change of Director's Interest Notice		27/09/11	72.55KB	Share
SNT	Share Trading Policy		26/09/11	161.77KB	Share
SNT	Appendix 3B - Employee Share Plan		30/08/11	98.95KB	Share
SNT	Change of Director's Interest Notice		26/08/11	71.74KB	Share
SNT	Appendix 3B - Exercise of Employee Options		26/08/11	97.48KB	Share
SNT	Ceasing to be a substantial holder		22/08/11	44.88KB	Share
SNT	Re-examination Documents Filed for EU Bronchitol Application	PRICE SENSITIVE	22/08/11	87.05KB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	12/08/11	250.07KB	Share
SNT	Change of Director's Interest Notice		08/08/11	73.97KB	Share
SNT	Appendix 3B exercise of options		04/08/11	97.48KB	Share
SNT	June 2011 Quarterly Report to Shareholders		20/07/11	2.05MB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	20/07/11	109.3KB	Share
SNT	Quarterly Investor Conference Call		19/07/11	21.58KB	Share
SNT	Bronchitol Resubmitted to Australian PBAC	PRICE SENSITIVE	12/07/11	85.36KB	Share
SNT	Re-examination of Bronchitol Marketing Application Requested	PRICE SENSITIVE	05/07/11	87.84KB	Share
SNT	Updated Investor Presentation		29/06/11	2.29MB	Share
SNT	Change of Director's Interest Notice		28/06/11	71.09KB	Share

SNTPharmaxis Announces New Board Appointment
25/07/12		88.67KB	Share
SNTAppendix 3B - Exercise of Employee Options
24/07/12		91.64KB	Share
SNTQuarterly Report to Shareholders - June 2012
17/07/12		272.81KB	Share
SNTAppendix 4C - quarterly
17/07/12	PRICE SENSITIVE	109.23KB	Share
SNTPharmaxis Quarterly Investor Conference Call
16/07/12		21.6KB	Share
SNTCeasing to be a substantial holder
10/07/12		28.64KB	Share
SNTBecoming a substantial holder
05/07/12		228.74KB	Share
SNTCeasing to be a substantial holder
04/07/12		46.82KB	Share
SNTProposed Issue of Performance Rights to CEO
02/07/12		94.61KB	Share
SNTAppendix 3B - Grant of Employee Performance Rights
02/07/12		96.56KB	Share
SNTAppendix 3B - Exercise of Employee Options
02/07/12		91.57KB	Share
SNT +UBSBecoming a substantial holder from UBS
29/06/12		233.56KB	Share
SNTChange of Director's Interest Notice
28/06/12		86.95KB	Share
SNTAppendix 3B
28/06/12		141.02KB	Share
SNTPHARMAXIS WELCOMES BRONCHITOL PBS LISTING ANNOUNCEMENT
25/06/12		82.26KB	Share
SNTCeasing to be a substantial holder
19/06/12		37.73KB	Share
SNTBecoming a substantial holder
15/06/12		217.01KB	Share
SNTAdditional Data Bronchitol Reduces Risk of Exacerbations
08/06/12	PRICE SENSITIVE	109.51KB	Share
SNTAppendix 3B - Exercise of Employee Options
01/06/12		97.54KB	Share
SNTBronchitol Commercial Progress in Europe
01/06/12	PRICE SENSITIVE	132.55KB	Share
SNTAppendix 3B - Exercise of employee options
21/05/12		97.6KB	Share
SNTPharmaxis Submits US New Drug Application for Bronchitol
21/05/12	PRICE SENSITIVE	83.46KB	Share
SNTAmended - Ceasing to be a substantial holder
16/05/12		61.89KB	Share
SNTCeasing to be a substantial holder
10/05/12		59.33KB	Share
SNTAppendix 3B Exercise of Employee Options
02/05/12		97.58KB	Share
SNTFinal Director's Interest Notice
01/05/12		11.59KB	Share
SNTPharmaxis Appoints New Chairman
01/05/12		77.38KB	Share
SNTInvestor Presentation
27/04/12		3.6MB	Share
SNTPharmaxis Receives Approval to Market Bronchitol in the EU
20/04/12	PRICE SENSITIVE	82.13KB	Share
SNTPharmaxis Quarterly Report to Shareholders March 2012
18/04/12		214.02KB	Share
SNTAppendix 4C - quarterly
18/04/12	PRICE SENSITIVE	109.33KB	Share
SNTPharmaxis Quarterly Investor Conference Call
17/04/12		21.55KB	Share
SNTPXS Completes Phase II study with ASM8 in asthma patients
17/04/12	PRICE SENSITIVE	108.62KB	Share
SNTBecoming a substantial holder
17/04/12		188.55KB	Share
SNTCeasing to be a substantial holder
13/04/12		26.48KB	Share
SNTBecoming a substantial holder
11/04/12		227.14KB	Share
SNTPharmaxis Announces Agreement for EU Supply of Bronchitol
29/03/12	PRICE SENSITIVE	80.08KB	Share
SNTEuropean Regulatiry Update on Bronchitol
16/03/12	PRICE SENSITIVE	78.65KB	Share
SNTBronchitol to be Reimbursed in Australia
14/03/12	PRICE SENSITIVE	83.48KB	Share
SNTChange of Director's Interest Notice
27/02/12		72.18KB	Share
SNTHalf Yearly Report and Accounts
03/02/12	PRICE SENSITIVE	267.62KB	Share
SNTAppendix 4C - quarterly
24/01/12	PRICE SENSITIVE	109.24KB	Share
SNTQuarterly Report to Shareholders
24/01/12		402.91KB	Share
SNTQuarterly Investor Conference Call
23/01/12		21.6KB	Share
SNTChange of Director's Interest Notice
30/12/11		70.18KB	Share
SNTBecoming a substantial holder
22/12/11		36.48KB	Share
SNTPharmaxis Files PBAC Minor Resubmission for Bronchitol
20/12/11	PRICE SENSITIVE	78.36KB	Share
SNTChange of Director's Interest Notice - D Hanley
16/12/11		73.05KB	Share
SNTChange of Director's Interest Notice - J Villiger
16/12/11		72.83KB	Share
SNTChange of Director's Interest Notice - Delaat
16/12/11		72.53KB	Share
SNTAppendix 3B - Exercise of Employee Options
16/12/11		97.6KB	Share
SNTAppendix 3B - Rights Offering Second Settlement
16/12/11		100.29KB	Share
SNTPhase 3 Trial in Bronchiectasis Reaches Recruitment Target
13/12/11	PRICE SENSITIVE	106.04KB	Share
SNTResults of Retail Entitlement Offer
13/12/11		80.92KB	Share
SNTAppendix 3B
29/11/11		100.87KB	Share
SNTChange of Director's Interest Notice
25/11/11		71.51KB	Share
SNTEntitlement Offer - Letter to Ineligible Shareholders
24/11/11		45.29KB	Share
SNTRetail Offer Booklet
24/11/11	PRICE SENSITIVE	2.1MB	Share
SNTResults of Meeting
22/11/11		82.89KB	Share
SNTCEO Presentation to 2011 AGM
21/11/11		2.72MB	Share
SNTChairman's Address 2011 AGM
21/11/11		84.97KB	Share
SNTInstitutional Component of Entitlement Offer
18/11/11	PRICE SENSITIVE	96.82KB	Share
SNTASX Circular - Entitlement Offer
16/11/11		52.54KB	Share
SNTAppendix 3B
16/11/11		101.51KB	Share
SNTNotice under section 708AA(2)(f)
16/11/11		40.98KB	Share
SNTCapital Raising Presentation
16/11/11		1.46MB	Share
SNTProRata Entitlement Offer to Raise up to Approximately $80m
16/11/11		40.62KB	Share
SNTTrading Halt
16/11/11	PRICE SENSITIVE	67.05KB	Share
SNTPharmaxis Announces PBAC Decision on Bronchitol
09/11/11	PRICE SENSITIVE	80.69KB	Share
SNTInvestor Presentation
25/10/11		1.73MB	Share
SNTReinstatement to Official Quotation
24/10/11	PRICE SENSITIVE	28.28KB	Share
SNTPharmaxis Announces Positive Bronchitol Opinion for Europe
24/10/11	PRICE SENSITIVE	104KB	Share
SNTInvestor Conference Call - Bronchitol EU Re-examination
21/10/11		22.08KB	Share
SNTSuspension from Official Quotation
20/10/11	PRICE SENSITIVE	151KB	Share
SNTTrading Halt
17/10/11	PRICE SENSITIVE	67.36KB	Share
SNTNotice of 2011 Annual General Meeting/Proxy Form
17/10/11		618.9KB	Share
SNTAppendix 4C - quarterly
12/10/11	PRICE SENSITIVE	109.05KB	Share
SNTQuarterly Report to Shareholders - September 2011
12/10/11		292.96KB	Share
SNTQuarterly Investor Conference Call
11/10/11		21.56KB	Share
SNTChange in substantial holding
10/10/11		53.71KB	Share
SNT2011 Annual Report to Shareholders
29/09/11		1.15MB	Share
SNTPhase II Trial in Allergic Asthma Completes Recruitment
29/09/11	PRICE SENSITIVE	90.81KB	Share
SNTUpdate on EU Bronchitol Marketing Application
28/09/11	PRICE SENSITIVE	91.48KB	Share
SNTChange of Director's Interest Notice
27/09/11		72.55KB	Share
SNTShare Trading Policy
26/09/11		161.77KB	Share
SNTAppendix 3B - Employee Share Plan
30/08/11		98.95KB	Share
SNTChange of Director's Interest Notice
26/08/11		71.74KB	Share
SNTAppendix 3B - Exercise of Employee Options
26/08/11		97.48KB	Share
SNTCeasing to be a substantial holder
22/08/11		44.88KB	Share
SNTRe-examination Documents Filed for EU Bronchitol Application
22/08/11	PRICE SENSITIVE	87.05KB	Share
SNTPreliminary Final Report
12/08/11	PRICE SENSITIVE	250.07KB	Share
SNTChange of Director's Interest Notice
08/08/11		73.97KB	Share
SNTAppendix 3B exercise of options
04/08/11		97.48KB	Share
SNTJune 2011 Quarterly Report to Shareholders
20/07/11		2.05MB	Share
SNTAppendix 4C - quarterly
20/07/11	PRICE SENSITIVE	109.3KB	Share
SNTQuarterly Investor Conference Call
19/07/11		21.58KB	Share
SNTBronchitol Resubmitted to Australian PBAC
12/07/11	PRICE SENSITIVE	85.36KB	Share
SNTRe-examination of Bronchitol Marketing Application Requested
05/07/11	PRICE SENSITIVE	87.84KB	Share
SNTUpdated Investor Presentation
29/06/11		2.29MB	Share
SNTChange of Director's Interest Notice
28/06/11		71.09KB	Share

REFRESH

First 6 7 8 9 10

(20min delay)
Last 2.4¢		Change 0.002(9.09%)		Mkt cap ! $28.65M

Open	High	Low	Value	Volume
2.2¢	2.5¢	2.2¢	$12.04K	509.9K

Buyers (Bids)

No.	Vol.	Price($)
1	82668	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	100000	1

View Market Depth

No.	Vol.	Price($)
1	82668	0.023
2	338839	0.022
5	1736248	0.021
11	2801008	0.020
2	999988	0.019

Price($)	Vol.	No.
0.024	100000	1
0.025	100000	1
0.026	50000	1
0.027	200000	1
0.028	500000	1

Last trade - 15.57pm 28/06/2024 (20 minute delay)


Last 2.5¢		Change 0.002 ( 13.6 %)
Open	High	Low	Volume
2.2¢	2.5¢	2.2¢	478642
Last updated 15.53pm 28/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories